Skip to content
Biotech’s contribution to America’s biodefense can only be supported through public-private partnerships, but the public sector must provide adequate support and private actors need […]
BIO 2025: A strong biodefense requires government-industry partnerships Read More »
The One Big Beautiful Bill Act – the “reconciliation bill” being considered by Congress – features policies that are crucial for driving American innovation.
Forty-five years ago, the Bayh-Dole Act enabled greater public-private partnership, supercharging U.S. innovation and helping make America a leader in biotech. The Bayh-Dole Coalition
Bayh-Dole Coalition promotes a law that supercharged innovation Read More »
Legislation introduced by Senators John Barrasso (R-WY) and Martin Heinrich (D-NM) would help protect the research and development of new treatments for patients with
Senators introduce bipartisan bill to protect new medicines for rare disease Read More »
Lawmakers questioned Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on key issues like vaccines, biosecurity, and federal research funds in a
Lawmakers question Kennedy on vaccines, biosecurity, and NIH cuts Read More »
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s “MAHA Report: Make Our Children Healthy Again,” released May 22, identifies the Trump administration’s
MAHA report takes issue with industry-funded research Read More »
Legislation to encourage rare disease drug development, enable tax deductions for research, and put checks on middlemen who drive up drug prices moved forward
House advances legislation on PBM reform, orphan drug support, R&D deductions Read More »
The Food and Drug Administration (FDA) added to a small list of gene-edited animals that can be used in the food supply chain with
FDA approves pig genetically engineered to resist disease Read More »
Tariffs on pharmaceuticals would harm supply chains that ensure we have enough medicines while threatening America’s security, economy, and biotech leadership, the Biotechnology Innovation
BIO’s comments on tariffs: There are better ways to strengthen U.S. biotech Read More »
Speaking on a recent Endpoints News panel, Nkarta CEO Paul Hastings discussed the impact of regulatory uncertainty and federal funding cuts on the investment
Nkarta’s Hastings discusses environment for biotech funding in Endpoints panel Read More »
